Continental Pharma Incorporated

G.d. Searle & Company

Sprl Franpharma

Michel R Franz

Georges E Lambelin

Joseph L Roba

Paul J Niebes

Daniel M Matagne

Andras B Vincze

Etienne T Hanon

Claude L Gillet

Alexis A Cordi

William R Van Dorsser

James E Truelove

Michel R Jans

Andreas B Vincze

Leo K Mathur

Alain V Polat

Robert G Cavalier

Kamlesh B Shah

Marianne P Oth

Philippe M Janssens De Varebeke

The present invention is related to a solid pharmaceutical composition comprising two separate regions,

Stabilised pharmaceutical composition comprising an extended release non-steroidal anti-inflammatory agent and an immediate release prostaglandin

Disclosed is a sustained release pharmaceutical dosage form including a drug and adapted to release the drug over an extended period of time. The dosage form comprises a capsule including a non-compressed bi-layer formulation; one layer comprising a drug release layer and the other a buoyant or floating layer, the pharmaceutical dosage form providing extended gastric residence time of the bi-layer formulation so that substantially all of the drug is released in the stomach over an extended period. The dosage form has a large diameter in relation to its size and an initial density of less than 1. The floating layer of the described pharmaceutical dosage form is formulated to provide buoyancy to the dosage form and diametral increase, the floating layer including a polymer which has the properties of a gelling agent and which upon contact with gastric fluid hydrates and forms a gelatinous barrier. The pharmaceutical dosage form is buoyant in gastric fluid for a period up to about 13 hours.

Sustained release, bilayer buoyant dosage form

A stabilized pharmaceutical composition which is an admixture of an NSAID selected from diclofenac and piroxicam, a prostaglandin and hydroxypropyl methylcellulose for maintaining the prostaglandin in a therapeutically effective amount without negatively affecting the therapeutic activity of the NSAID.

Stabilized pharmaceutical admixture composition

2-Pentanoylaminoacetic acid and pharmaceutically suitable salts thereof are claimed for use as pharmaceuticals. The compounds are useful in producing an effect on the central nervous system, especially in the treatment of various forms of epilepsy, of disninesiae, of parkinsonism, of memory troubles, of psychic troubles and of cerebral anoxia.

Derivatives of 2-aminoacetic acid

Method for the preparation of micronized p-butoxyphenylacetylhydroxamic acid, comprising dissolving the p-butoxyphenylacetylhydroxamic acid in a basic solution of salifying agent and then precipitating it in an acid solution in the presence of a surface-active agent.

Method for the preparation of p-butoxyphenylacetyl-hydroxamic acid in

A salt of (+)-catechin formed of the reaction product of (+)-catechin with at least a basic amino-acid, such as L-lysine and L-arginine; a hydrosoluble double salt is formed by the reaction product of (+)-catechin with a basic amino-acid, such as L-lysine and L-arginine, and another inorganic or organic acid.

Salts of (+)-catechine, their preparation and use, and compositions

A pharmaceutical composition for treating degenerative diseases of the articular cartilage, in particular osteoarthritis and chondromalacia, and of the degenerative processes of the articular cartilage resulting from other diseases, such as rheumatoid arthritis, this composition containing (+) - catechin and/or one of the salts thereof as an active products, said composition being administered orally, rectally, intra-articularly, intravenously or topically.

Pharmaceutical composition and therapeutical method for treating

Growing community of inventors

Brussels, Belgium

Michel R Franz